Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients

Clinica Chimica Acta

Volumn 421, Issue , 2013, Pages 157-163

  Willrich, Maria Alice V ^a   Rodrigues, Alice C ^a   Cerda, Alvaro ^a   Genvigir, Fabiana D V ^a   Arazi, Simone S ^a   Dorea, Egidio L ^a   Bernik, Marcia M S ^a   Bertolami, Marcelo C ^b   Faludi, Andre ^b   Largura, Alvaro ^c   Baudhuin, Linnea M ^d   Bryant, Sandra C ^d   Hirata, Mario Hiroyuki ^a   Hirata, Rosario Dominguez Crespo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto Dante Pazzanezze   (Brazil)

^c Paranalise Laboratory   (Brazil)

^d MAYO CLINIC   (United States)

Author keywords

Atorvastatin; CYP3A activity; CYP3A4; CYP3A5; MRNA expression; Pharmacogenomics

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CREATINE KINASE; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; HAPLOTYPES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHENOTYPE; PYRROLES; RNA, MESSENGER;

EID: 84876331758     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.03.007     Document Type: Article

References (42)

1. Shitara Y., Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112:71-105.
2. Brown M.S., Goldstein J.L. Lowering plasma cholesterol by raising LDL receptors. N Engl J Med 1981, 305:515-517.
3. Wang C.Y., Liu P.Y., Liao J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008, 14:37-44.
4. Vladutiu G.D. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008, 20:648-655.
5. Neuvonen P.J., Backman J.T., Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008, 47:463-474.
6. Neuvonen P.J. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 2010, 11:323-332.
7. Grube M., Kock K., Oswald S., et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 2006, 80:607-620.
8. Zanger U.M., Turpeinen M., Klein K., Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008, 392:1093-1108.
9. Wojnowski L., Hustert E., Klein K., et al. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 2002, 94:630-631. [author reply 631-632].
10. Lamba V., Panetta J.C., Strom S., Schuetz E.G. Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther 2010, 332:1088-1099.
11. Rodrigues A.C., Hirata M.H., Hirata R.D. The genetic determinants of atorvastatin response. Curr Opin Mol Ther 2007, 9:545-553.
12. Kocarek T.A., Dahn M.S., Cai H., Strom S.C., Mercer-Haines N.A. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos 2002, 30:1400-1405.
13. Watanabe M., Kumai T., Matsumoto N., et al. Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver. J Pharmacol Sci 2004, 94:459-462.
14. Takagi S., Nakajima M., Mohri T., Yokoi T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 2008, 283:9674-9680.
15. Willrich M.A., Hirata M.H., Hirata R.D. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics 2009, 10:1017-1024.
16. Cerda A., Genvigir F.D., Arazi S.S., et al. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin. Clin Chim Acta 2010, 411:631-637.
17. Haas C.E., Brazeau D., Cloen D., et al. Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. Eur J Clin Pharmacol 2005, 61:583-593.
18. Siest G., Jeannesson E., Marteau J.B., et al. Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab Dispos 2008, 36:182-189.
19. Genvigir F.D., Rodrigues A.C., Cerda A., et al. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells. Pharmacogenomics 2010, 11:1235-1246.
20. Willrich M.A., Hirata M.H., Genvigir F.D., et al. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin Chim Acta 2008, 398:15-20.
21. Chahoud G., Aude Y.W., Mehta J.L. Dietary recommendations in the prevention and treatment of coronary heart disease: do we have the ideal diet yet?. Am J Cardiol 2004, 94:1260-1267.
22. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
23. Salazar L.A., Hirata M.H., Cavalli S.A., Machado M.O., Hirata R.D. Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin Chem 1998, 44:1748-1750.
24. Cavalli S.A., Hirata M.H., Hirata R.D. Detection of MboII polymorphism at the 5' promoter region of CYP3A4. Clin Chem 2001, 47:348-351.
25. Vandesompele J., De Preter K., Pattyn F., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. [RESEARCH0034].
26. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
27. Rouits E., Boisdron-Celle M., Morel A., Gamelin E. Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6beta-hydroxycortisol in routine practice. For CYP 3A4 activity evaluation in basal conditions and after grapefruit juice intake. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 793:357-366.
28. Lake S.L., Lyon H., Tantisira K., et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003, 55:56-65.
29. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002, 70:425-434.
30. Silbiger V.N., Hirata M.H., Luchessi A.D., et al. Differentiation of African components of ancestry to stratify groups in a case-control study of a Brazilian urban population. Genet Test Mol Biomarkers 2012, 16:524-530.
31. Suarez-Kurtz G. Pharmacogenomics and the genetic diversity of the Brazilian population. Cad Saude Publica 2009, 25:1650-1651.
32. Suarez-Kurtz G., Genro J.P., de Moraes M.O., et al. Global pharmacogenomics: impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J 2012, 12:267-276.
33. Rosales A., Alvear M., Cuevas A., Saavedra N., Zambrano T., Salazar L.A. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. Clin Chim Acta 2012, 413:495-501.
34. Wang D., Guo Y., Wrighton S.A., Cooke G.E., Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011, 11:274-286.
35. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27:383-391.
36. Galteau M.M., Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 2003, 59:713-733.
37. Honda A., Miyazaki T., Ikegami T., et al. Cholesterol 25-hydroxylation activity of CYP3A. J Lipid Res 2011, 52:1509-1516.
38. Diczfalusy U., Bjorkhem I. Still another activity by the highly promiscuous enzyme CYP3A4: 25-hydroxylation of cholesterol. J Lipid Res 2011, 52:1447-1449.
39. Shinkyo R., Guengerich F.P. Inhibition of human cytochrome P450 3A4 by cholesterol. J Biol Chem 2011, 286:18426-18433.
40. Ozdemir V., Kalow W., Tang B.K., et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000, 10:373-388.
41. Mancia G., De Backer G., Dominiczak A., et al. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
42. WHO World Health Organization Global information system on alcohol and death. Definition of an alcoholic dose Available at. http://www.who.int/gho/alcohol/en/index.html.